The Chinese vaccine was allowed in 4 Latin American countries, including Argentina. With this measure, there are currently 11 vaccines approved by the United Nations health agency.
The World Health Organization (WHO) today approved the COVID-19 vaccine, called Convidecia, by the Chinese company CanSino Biologics. After reviewing data submitted by the company and another set of audits, the healthcare organization added it to the list of vaccines that have demonstrated safety and efficacy in reducing the risk of complications and death from coronavirus infection. Currently, there are 11 vaccines approved by WHO.
This Vaccine from CanSino Biologics It is currently authorized for use in 10 countries: Argentina, Mexico, Chile, China, Ecuador, Hungary, Indonesia, Malaysia, Pakistan and the Republic of Moldova.
Through the emergency use list procedure, WHO assesses the quality, safety and efficacy of vaccines as a prerequisite for vaccine supply through the COVAX mechanism, which enables low-income countries to guarantee access to vaccinate more people. In addition, the health agency procedure allows countries to expedite their regulatory approvals to import and administer COVID-19 vaccines.
Moreover CanSino vaccine Vaccines from Pfizer/BioTech, AstraZeneca, Janssen-Cilag, Moderna, Sinopharm, Bharat Biotech, Novavax and two vaccines produced at the Serum Institute of India have already received WHO approval. In contrast, the Sputnik vaccine has not yet completed the international health organization’s evaluation process.
The Chinese vaccine is based on a modified human adenovirus that expresses the Spike protein of the SARS-CoV-2 coronavirus. It is given as a single dose. It was originally developed by the CanSino company in cooperation with the Biology Institute of the Chinese Military Academy of Medical Sciences.
In May 2020, researchers published promising results from the phase 1 safety trial of Convidecia, and reported in July that phase 2 trials showed the vaccine produced a potent immune response. The Chinese military approved this vaccine as a “specially needed drug” on June 25 of that year.
As of August 2020, CanSino has started phase 3 trials in various countries including Pakistan, Russia, Mexico, Argentina and Chile. On February 25, 2021, China announced the approval of the CanSino vaccine for general use. Results of the phase 3 trial published in the journal Lancet In December 2021 they demonstrated that Convidecia has high efficacy against severe Covid-19 disease.
Volunteers from eleven clinical research centers in Argentina participated in the Phase 3 study of the CanSino vaccine against COVID-19. In addition, other studies are currently being carried out in the country. A vaccine study is underway in a cohort of people living with HIV at 4 centers, and another study on heterologous vaccination is being conducted at 7 centres. In this latest trial, the CanSino vaccine is used as a second dose in people who have received their first dose of Sputnik V, produced by Russia’s Gamaleya Institute.
Over time, the efficacy of a single dose of Convidencia has been observed to decrease, and researchers began testing booster doses. In January 2022, researchers in China reported that the inhaled booster of the same vaccine was safe and produced very high levels of antibodies. Against coronavirus when given to people who have received a different vaccine initially.
On February 19, Chinese health authorities approved Convidencia for use as a booster in people who had originally received other vaccines. So far, Convidecia has been approved as a heterologous enhancer in China, Argentina, Malaysia and Indonesia. Moreover It is the first and only adenovirus vectored vaccine included in the heterologous vaccination program in China.
As reported by WHO, the Cansino vaccine received its approval after “reviewing the data on quality, safety, efficacy, risk management plan, compliance with schedule and inspection of the production site”. The Technical Advisory Group for the Emergency Use List, convened by WHO and composed of regulatory experts from around the world, has determined that “the vaccine meets WHO standards for protection against COVID-19 and that the benefits of the vaccine far outweigh the risks. ”
Cansino Biologics’ vaccine was also reviewed earlier this month by WHO’s Strategic Advisory Group on Immunization (SAGE), which formulated specific policies and recommendations regarding the use of vaccines in populations. (i.e. recommended age groups, intervals between injections, specific groups such as pregnant and lactating women).
SAGE is recommended use of the vaccine as a single dose (0.5 ml) in all age groups from 18 years of age. The vaccine has been shown to be 64% effective against symptomatic disease and 92% effective against severe COVID-19.
The vaccine induces an immune response: 14 days after vaccination, it produces specific neutralizing antibodies against Spike protein, with a maximum peak at day 28. The immune response, in addition to being mediated by antibodies, has the involvement of CD4+ and CD8+. T cell response.
Source: Info Bae